Singular Genomics Systems, Inc. Overview
Pro stress-test →Singular Genomics Systems is a life science technology company developing next-generation sequencing (NGS) and spatial multiomics platforms for researchers and clinicians. The company went private in February 2025 after being acquired by Deerfield Management. It designs benchtop genomic sequencers and associated consumables to democratize access to advanced genomic analysis.
Strategic Profile
Pro stress-test →Singular Genomics competes in the NGS platform market with its G4 benchtop sequencer and emerging PX instrument for spatial analysis. The company positions itself on versatility, speed, and accuracy, targeting researchers and clinical laboratories seeking flexible genomic solutions. Following privatization, the company is focused on expanding its installed base and advancing its multiomics product pipeline.
Competitive Landscape
Pro stress-test →Singular Genomics competes in the benchtop NGS sequencing market dominated by Illumina (iSeq, MiSeq, NextSeq platforms) and to a lesser extent, Ion Torrent (Thermo Fisher) and emerging players like Oxford Nanopore. The company differentiates on benchtop form factor, versatility, and emerging spatial multiomics capabilities via the G4X platform. Competitors like 10x Genomics dominate single-cell analysis but use Singular's platform as a compatible sequencing engine, creating partnership potential rather than pure competition.
Industry Context
Singular Genomics Systems, Inc. operates in Benchtop next-generation sequencing platforms.
Key facts
Founded: 2016 · Headquarters: San Diego, California · Employees: 162 (as of May 2026) · Revenue: $1.0M (Q4 2023); minimal historical revenues